Induction of IL-1 Ra in Resistant and Responsive Hepatitis C Patients Following Treatment with IFN-con 1

Hepatitis C virus (HCV) infection is resistant to interferon-a (IFN-a) in some patients. The mechanism of this resistance is unknown. Interleukin-1 receptor antagonist (IL-1Ra) is induced by IFN-a and is a good indicator of IFN activity. In the current study, we compared IL-1Ra levels in rapid virologic responders and flat responders who showed resistance to IFN. Three groups of patients were examined, including those who received a single dose of consensus IFN (IFN-con1), patients who received daily IFN-con1 for 1 week, and patients who received IFN-con1 daily for 24 weeks. Serum IL-1Ra, IL-6, and HCV RNA were measured serially in all groups. Serum IL-1Ra levels increased rapidly in all patients with hepatitis C after IFN-a administration, irrespective of their virologic response. IL-1Ra levels remained elevated at 1 week but were similar to baseline by week 2 of treatment in patients receiving continuous therapy. IL-6 levels also increased acutely but rose more slowly than IL-1Ra levels. The increase in IL-1Ra and IL-6 observed in both flat and rapid virologic responders indicates that IFN receptors are functioning in patients with IFN-resistant hepatitis C and that the lack of response is related to other virologic or immunologic factors.

[1]  D. Ganger,et al.  An analysis of acute changes in interleukin-6 levels after treatment of hepatitis C with consensus interferon. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[2]  G. Fantuzzi,et al.  Production of IL‐1 receptor antagonist by hepatocytes is regulated as an acute‐phase protein in vivo , 2001, European journal of immunology.

[3]  M. Shiffman,et al.  Alpha interferon combined with ribavirin potentiates proliferative suppression but not cytokine production in mitogenically stimulated human lymphocytes. , 2000, Antiviral research.

[4]  A. Neumann,et al.  Hepatitis C Virus Kinetics , 1999, Antiviral therapy.

[5]  T. Layden,et al.  Hepatitis C viral dynamics. , 1999, Clinics in liver disease.

[6]  M. Jackson,et al.  Comparison of cytotoxic T‐lymphocyte responses to hepatitis C virus core protein in uninfected and infected individuals , 1999, Journal of medical virology.

[7]  A Sette,et al.  Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. , 1999, Journal of immunology.

[8]  M. Davis,et al.  Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[9]  P. Transidico,et al.  Characterization of type II intracellular IL‐1 receptor antagonist (IL‐1ra3): a depot IL‐1ra , 1999, European journal of immunology.

[10]  J. McHutchison,et al.  Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. , 1999, Seminars in liver disease.

[11]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[12]  G. Davis,et al.  Intrahepatic hepatitis C virus–specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C , 1998, Hepatology.

[13]  M. Katze,et al.  Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. , 1998, Pharmacology & therapeutics.

[14]  A. Sanyal,et al.  Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C , 1997, Hepatology.

[15]  F. Capron,et al.  Interleukin-1 receptor antagonist plasma concentration is specifically increased by alpha-2A-interferon treatment. , 1997, Journal of hepatology.

[16]  L. Blatt,et al.  Type 1 interferon as an antiinflammatory agent: inhibition of lipopolysaccharide-induced interleukin-1 beta and induction of interleukin-1 receptor antagonist. , 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[17]  H. Tilg,et al.  Induction of circulating IL-1 receptor antagonist by IFN treatment. , 1993, Journal of immunology.

[18]  E. Maeyer,et al.  Immuno-modulating properties of interferons. , 1982 .

[19]  E. de Maeyer,et al.  Immuno-modulating properties of interferons. , 1982, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.